Skip to main content
. 2018 May 8;23(10):1178–1187. doi: 10.1634/theoncologist.2017-0573

Figure 1.

image

Kaplan‐Meier estimates of first PFS (A), second PFS (B), and overall survival (C) in patients who received trifluridine/tipiracil followed by regorafenib (continuous line) or the reverse sequence (dashed line).

Abbreviations: CI, confidence interval; HR, hazard ratio; PFS, progression‐free survival.